News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ZIOPHARM Oncology, Inc. (ZIOP.OB) Announces Poster Presentation at the 2013 American Society of Clinical Oncology Annual Meeting



5/16/2013 10:06:12 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BOSTON, May 15, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Gerald P. Linette, MD, PhD, of the Washington University School of Medicine, will present updated clinical results from a Phase 1 study of Ad-RTS-hIL-12, a novel DNA-based therapeutic candidate in advanced melanoma at the 2013 American Society for Clinical Oncology (ASCO) Annual Meeting being held May 31 – June 4, 2013 at McCormick Place in Chicago, IL. Results will be presented during the Developmental Therapeutics – Immunotherapy Poster Discussion Session on Saturday, June 1st from 1:15 pm – 5:15 pm CT in a poster titled: "A phase I open-label study of ?d-RTS-hIL-12, an adenoviral vector engineered to express hIL-12 under the control of an oral activator ligand, in subjects with unresectable stage III/IV melanoma." (Poster Board #14, Room #S405). Immediately following, the poster will be included in the discussion session beginning at 5:15pm CT in Room #S406.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES